逍遙散出自《太平惠民和劑局方》,具疏肝健脾養(yǎng)血、理氣調(diào)情怡性之效,原為婦人之疾所設(shè),后世在其核心組方基礎(chǔ)上衍生黑逍遙散、丹梔逍遙散等系列加減方,應(yīng)用范圍從婦科拓展至多學(xué)科,近年在腫瘤領(lǐng)域研究頗豐。通過(guò)方證、機(jī)制及臨床應(yīng)用3方面梳理其在惡性腫瘤中的價(jià)值。發(fā)現(xiàn)本核心組方以“和”“疏”為要,兼具扶正祛邪之功;機(jī)制上通過(guò)調(diào)控腫瘤細(xì)胞增殖、自噬、凋亡及腫瘤微環(huán)境、外泌體、代謝重編程等發(fā)揮作用,分子機(jī)制明確且經(jīng)體內(nèi)外實(shí)驗(yàn)驗(yàn)證;臨床可阻斷癌前病變,聯(lián)合常規(guī)西醫(yī)療法減毒增效,改善終末期患者生活質(zhì)量,對(duì)腫瘤相關(guān)抑郁、失眠等并發(fā)癥療效確切,且安全性高、適合長(zhǎng)期服用。為其臨床推廣、中西醫(yī)協(xié)作及抗腫瘤藥物研發(fā)提供參考。

Xiaoyao San (逍遙散), derived from Formulary of the Bureau of Taiping People’s Welfare Pharmacy, possesses the effects of soothing the liver, strengthening the spleen, nourishing blood, regulating qi, and calming the mind. Initially formulated for gynecological diseases, it has since derived a series of modified prescriptions such as Hei Xiaoyao San (黑逍遙散) and Danzhi XiaoYao San (丹梔逍遙散) based on its core composition, with applications extended from gynecology to multiple disciplines. In recent years, increasing research has focused on its use in treating tumors and related conditions. This article systematically reviews the value of Xiaoyao San in malignant tumors from three aspects: formula-syndrome analysis, mechanism research, and clinical application. It is found that the core prescription focuses on “harmonizing” and “soothing”, with both the functions of strengthening healthy qi and eliminating pathogenic factors. Mechanistically, it exerts anti-tumor effects by regulating tumor cell proliferation, autophagy, apoptosis, tumor microenvironment, exosomes, and metabolic reprogramming, with clear molecular mechanisms verified by in vivo and in vitro experiments. Clinically, it can block precancerous lesions, enhance efficacy and reduce toxicity when combined with conventional Western therapies, improve the quality of life of end-stage patients, and has definite curative effects on tumor-related complications such as depression and insomnia. It is highly safe and suitable for long-term use by tumor patients. This review provides references for the clinical promotion of Xiaoyao San and its core modified prescriptions, the collaboration between traditional Chinese and Western medicine, and the development of antitumor drugs.

R285

全國(guó)名老中醫(yī)藥專家傳承工作室建設(shè)項(xiàng)目（國(guó)中醫(yī)藥人教函[2022]75號(hào)）；全國(guó)名中醫(yī)傳承工作室建設(shè)項(xiàng)目（國(guó)中醫(yī)藥人教函[2022]245號(hào)）；中西醫(yī)防治重大疾病河南省協(xié)同創(chuàng)新中心（教科技[2023]413號(hào)）；河南中醫(yī)藥大學(xué)2024年度研究生科研創(chuàng)新能力提升計(jì)劃（2024KYCX009，2024KYCX013）